Scarica l'app Stockscreener
26.74
0.19%
-0.05
Pre-mercato:
26.51
-0.23
-0.86%
Precedente Chiudi:
$26.79
Aprire:
$26.845
Volume 24 ore:
1.53M
Relative Volume:
0.78
Capitalizzazione di mercato:
$1.93B
Reddito:
Utile/perdita netta:
$-368.95M
Rapporto P/E:
-4.8221
EPS:
-5.5453
Flusso di cassa netto:
$-293.81M
1 W Prestazione:
-10.06%
1M Prestazione:
-20.58%
6M Prestazione:
-38.46%
1 anno Prestazione:
-13.74%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$26.38
$30.51
Portata 52W:
$23.05
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
26.74 | 1.93B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-12 | Iniziato | Leerink Partners | Market Perform |
| 2026-03-11 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Five new hires at Vera Therapeutics received share options and awards that vest over four years. - Stock Titan
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics CFO Young Joseph R Exercises 5,000 Stock Options at $3.94 (NASDAQ: VERA) - Kalkine Media
Vera Therapeutics (VERA) finance SVP adds 5,000 shares - Stock Titan
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com Canada
Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction By Investing.com - Investing.com India
Centrus Announces Proposed Public Underwritten Offering of Class A Common Stock and Warrants - Yahoo Finance
Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan - Kalkine Media
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Discipline and Rules-Based Execution in VERA Response - Stock Traders Daily
Vera Therapeutics (NASDAQ: VERA) insider to sell tens of thousands of shares - Stock Titan
Vera Therapeutics stock gains after fresh analyst support - ad-hoc-news.de
Vera Therapeutics to Participate at Upcoming Investor Conferences - manilatimes.net
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Vera Therapeutics options activity points to institutional bullish call spread on September strikes - investing.com
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - simplywall.st
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com Nigeria
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Canada
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com South Africa
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com India
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com Australia
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com India
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 15 '26 |
Sale |
37.00 |
18,500 |
684,500 |
235,244 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
Sep 11 '26 |
Option Exercise |
3.94 |
5,000 |
19,698 |
80,754 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Sale |
35.12 |
18,500 |
649,642 |
235,244 |
| MARSHALL FORDYCE | Director |
Sep 02 '26 |
Proposed Sale |
34.23 |
64,750 |
2,216,392 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Sep 02 '26 |
Option Exercise |
2.90 |
18,500 |
53,591 |
253,744 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jul 07 '26 |
Sale |
42.30 |
46,250 |
1,956,187 |
151,994 |
| MARSHALL FORDYCE | Director |
Jun 23 '26 |
Proposed Sale |
38.43 |
74,000 |
2,843,820 |
0 |
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
| Fordyce Marshall | PRESIDENT AND CEO |
May 12 '26 |
Sale |
36.74 |
18,500 |
679,747 |
216,744 |
| MARSHALL FORDYCE | Director |
May 12 '26 |
Proposed Sale |
36.61 |
18,500 |
677,285 |
0 |
0.73%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):